P0544
INNATE AND ADAPTIVE IMMUNE RESPONSES CORRELATE
WITH PEGINTERFERON ALFA TREATMENT EFFICACY IN CHRONIC
HEPATITIS B PATIENTS (THE OSST IMMUNOLOGY STUDY)
W. Yan1, D. Wu1, X. Wang1, Q. Lai2, Q. Zheng2, J. Jiang3, J. Hou2,
M. Han1, Q. Ning1. 1Department and Institute of Infectious Disease,
Tongji Hospital, Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, 2Hepatology Unit and Department
of Infectious Diseases, Nanfang Hospital, Southern Medical University,
Guangzhou, 3Department of Liver Diseases Research Center, First
Affiliated Hospital of Fujian Medical University, Fuzhou, China
E-mail: [email protected]
Background and Aims: The aim of this study was to characterize
the immunological features responsible for improved treatment
responses in 77 patients with chronic hepatitis B (CHB) treated
with peginterferon (Peg IFN) alfa-2a after switching them from
entecavir (ETV) therapy.
Methods: Peripheral natural killer (NK) cells, Toll-like receptors
(TLRs), T cells, regulatory T cells (Tregs) and programmed death 1
(PD-1) were evaluated dynamically by flow cytometry. Response
was defined as hepatitis B e antigen (HBeAg) seroconversion,
hepatitis B surface antigen (HBsAg) loss, and HBsAg seroconversion
(either as singular events or in combination at week 48)
Results: From week 12 to week 24, compared with ETV responders
or Peg IFN alfa non-responders, Peg IFN alfa responders exhibited a
significant decline in Treg proportions as well as a diminished
negative regulation of CD8+ T cells by Tregs. Those HBeAgnegative
patients at baseline treated with Peg IFN alfa also showed
significantly decreased Treg proportions and a higher rate of
HBsAg seroconversion. Moreover, Peg IFN alfa responders showed
a significantly higher increase in the NKG2C+ NK cell proportions
from baseline to week 12 and of TLR2+ monocytes at week 12 than
Peg IFN alfa non-responders.
Conclusions: Successful response to Peg IFN alfa correlates with
an early significant restoration of impaired immune responses.
Although antiviral treatment response can be achieved by both
IFN and ETV, the underlying immunological features vary which
may explain the generally observed difference in off-treatment
durability of response between the two treatments, as well as
effects on HBsAg.
negative regulation of CD8+ T cells by Tregs. Those HBeAg negative
patients at baseline treated with Peg IFN alfa also showed
significantly decreased Treg proportions and a higher rate of
HBsAg seroconversion. Moreover, Peg IFN alfa responders showed
a significantly higher increase in the NKG2C+ NK cell proportions
from baseline to week 12 and of TLR2+ monocytes at week 12 than
Peg IFN alfa non-responders 作者: StephenW 时间: 2015-4-24 17:01